Barclays Capital Analysts Initiate Coverage on Gilead Sciences (GILD)

Equities research analysts at Barclays Capital (NYSE: BCS) assumed coverage on shares of Gilead Sciences (NASDAQ: GILD) in a research note issued to investors on Friday. They set an “overweight” rating and a $67.00 price target on the stock.

Separately, analysts at Morgan Stanley (NYSE: MS) initiated coverage on shares of Gilead Sciences in a research note to investors on Friday. They set an “overweight” rating on the stock. Analysts at UBS AG (NYSE: UBS) raised their price target on shares of Gilead Sciences from $53.00 to $61.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Also, analysts at ThinkEquity raised their price target on shares of Gilead Sciences from $50.00 to $61.00 in a research note to investors on Monday. They now have a “buy” rating on the stock.

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company. The Company focuses on the development and commercialization of human therapeutics for life threatening diseases. The Company has operations in North America, Europe and Asia Pacific. The Company’s products include Truvada, Atripla, Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa, Vistide and Cayston. Its products are marketed through its commercial teams and/or in conjunction with third-party distributors and corporate partners. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. On July 8, 2010, the Company acquired CGI Pharmaceuticals, Inc. (CGI).

Shares of Gilead Sciences traded up 0.02% during mid-day trading on Friday, hitting $53.74. Gilead Sciences has a one year low of $34.45 and a one year high of $56.50. The stock’s 50-day moving average is $46.31 and its 200-day moving average is $41.1. The company has a market cap of $40.472 billion and a P/E ratio of 15.14.

Stay ahead of the market with Analyst Ratings Network's daily email update that provides a summary of analysts' upgrades, downgrades and new coverage. Click here to register now.

Posted by Web Inquirer Staff on 10 Feb 2012. Filed under Markets. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.